GT Biopharma Demonstrates Novel B7-H3 Targeting Dual Camelid Nanobody BiKE and GTB-5550 Induce NK Cell Activation Against Broad Spectrum of Tumors at ESMO IO Congress 2021
/PRNewswire/ GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based.
/PRNewswire/ GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based.
At the end of the latest market close, GT Biopharma Inc. (GTBP) was valued at $3.78. In that particular session, Stock kicked-off at the price of $3.77 while reaching the peak value of $3.8655 and lowest value recorded on the day was $3.12. The stock current value is $3.15.Recently in News on Novemb
ESMO-IO will publish full abstracts on their website on Thursday, December 2 at 12:00 pm CET . GT Biopharma will post its poster on the company s website in the "Presentations" section during the conference.